Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 28:93:104281.
doi: 10.1016/j.iccn.2025.104281. Online ahead of print.

Body mass index and mortality: The "Obesity Paradox" in critically ill patients with intra-abdominal infection or sepsis - An international cohort study

Fien Donckels  1 , Massimo Antonelli  2 , Kostoula Arvaniti  3 , Ben Creagh-Brown  4 , Elena Conoscenti  5 , Dylan W de Lange  6 , Gennaro De Pascale  2 , Jan De Waele  7 , Mieke Deschepper  8 , Yalim Dikmen  9 , George Dimopoulos  10 , Christian Eckmann  11 , Guy Francois  12 , Massimo Girardis  13 , Despoina Koulenti  14 , Sonia Labeau  15 , Jeffrey Lipman  16 , Emilio Maseda  17 , Philippe Montravers  18 , Adam Mikstacki  19 , Jose-Artur Paiva  20 , Georgios Papathanakos  21 , Jordi Rello  22 , Jean-Francois Timsit  23 , Dirk Vogelaers  24 , Stijn Blot  25 ; Abdominal Sepsis Study AbSeS group on behalf of the Trials Group of the European Society of Intensive Care Medicine
Affiliations

Body mass index and mortality: The "Obesity Paradox" in critically ill patients with intra-abdominal infection or sepsis - An international cohort study

Fien Donckels et al. Intensive Crit Care Nurs. .

Abstract

Objective: To assess the relationship between body mass index (BMI, i.e., kg/m2) and mortality in ICU patients with intra-abdominal infection or sepsis.

Methods: This is a secondary analysis from AbSeS, an international, observational cohort study including patients with intra-abdominal infection (n = 2588). Patients were classified as underweight (BMI < 18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), or obese (BMI ≥ 30). Independent relationships with mortality were assessed by logistic and Cox regression. Results reported as odds ratios (OR) or hazard ratios (HR) 95 % and confidence interval (CI). Sensitivity analyses were performed for age (<65 or ≥ 65 years), sex, and sepsis or septic shock.

Results: Overall mortality was 29.1 %. Logistic regression showed underweight to be associated with increased mortality (OR 1.76, 95 % CI 1.12-2.78), while obesity was independently associated with a decreased mortality risk compared to normal weight patients (OR 0.75, 95 % CI 0.58-0.97). Mortality in overweight patients was not different from patients with a normal weight. In patients < 65 years, the association with underweight remained, while obesity was no longer associated with decreased mortality. All significant relationships between BMI and mortality disappeared when only considering patients ≥ 65 years. Underweight was associated with increased mortality in patients with sepsis, but not in septic shock. In Cox regression, underweight remained an independent risk factor for death (HR 1.72, 95 % CI 1.25-2.35), whereas obesity was no longer associated with a decreased mortality risk.

Conclusion: In the context of intra-abdominal infection in ICU patients, underweight is independently associated with increased mortality. The possible association of obesity with decreased mortality risk is less robust.

Implications for clinical practice: Nutritional screening should be part of preoperative evaluation in elective abdominal surgery. If undernutrition is identified, targeted nutritional support should be initiated early to improve postoperative resilience and potentially reduce mortality risk in case of critical illness.

Keywords: Abdominal infection; Body mass index; ICU; Mortality; Obesity; Sepsis; Underweight.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest • Stijn Blot is Editor-in-Chief of Intensive & Critical Care Nursing and was not involved in the editorial review or the decision to publish the article. • Received grants related to the submitted work: S. Blot (Pfizer) • Received honoraria or grants outside the submitted work: M. Antonelli (Fresenius, Pfizer, Toray); J. De Waele (Research Foundation Flanders, Pfizer, MSD, Thermofisher); C. Eckmann (Merck, Pfizer); E. Maseda (Astellas Pharma, Pfizer, MSD); P. Montravers (Pfizer, MSD, Menarini, Unyvero, Viatris) • All other authors: no conflict of interest.

LinkOut - more resources